Horizon Kinetics Medical ETF
MEDX
Market cap $12.5M

27.15 USD

+0.51

1.91%

At close Apr 30, 4:00 PM EDT

1 day

1.91%

5 days

4.34%

1 month

-1.88%

3 months

-0.95%

6 months

-8.15%

Year to date

3.23%

1 year

-2.55%

5 years

-13.12%

10 years

-13.12%

Funds holding %

of 7,425 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

506% more capital invested

Capital invested by funds: $71.3K [Q3] → $432K (+$360K) [Q4]

75% more funds holding

Funds holding: 4 [Q3] → 7 (+3) [Q4]

3.05% more ownership

Funds ownership: 0.54% [Q3] → 3.59% (+3.05%) [Q4]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for MEDX.

See Analyst Rankings

Financial journalist opinion

Positive

Zacks Investment Research

11 months ago

ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook

Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.

Positive

Zacks Investment Research

1 year ago

ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat

Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.

See News Rankings

Charts implemented using Lightweight Charts™